RPE65 and Leber congenital amaurosis: Over 2 decades, at least five different adeno-associated virus (AAV)-RPE65 products were tested using mouse and canine models of Leber congenital amaurosis 2 (LCA2), which led to a total of 13 clinical trials (Maguire et al., 2021).